Products Description

Oseltamivir Phosphate is a selective neuraminidase inhibitor used to treat and prevent influenza A and B infections. It blocks viral replication by preventing the release of virus particles from infected cells, reducing both symptom severity and illness duration. The product is available as capsules for adults and older children, and as an oral suspension for pediatric patients or those who cannot swallow capsules, ensuring accurate and convenient dosing.

Oseltamivir is rapidly absorbed and converted into its active metabolite, providing effective systemic antiviral activity. This product offers a reliable and flexible solution for managing influenza across different age groups.

product-204-132

Product Application

Oral Capsules

Oral Solution

Oral Suspension

Prophylactic Medication

Mechanism of Action

After the influenza virus infects host cells, it replicates inside the cells and forms new viral particles, which "bud" from the cell surface. Under normal circumstances, neuraminidase on the viral surface cleaves sialic acid residues on the host cell membrane, helping the newly formed viruses detach from the cell surface and be released to the outside, where they continue to infect other healthy cells. In the diagram, oseltamivir binds to the neuraminidase on the viral surface and inhibits its activity, preventing the viruses from being smoothly released from already infected cells, causing the viral particles to be blocked and retained on the cell surface.

This process effectively prevents further spread of the virus within the body, thereby alleviating symptoms, shortening the course of the disease, and reducing the likelihood of new cells becoming infected.

Formulation Note

Oseltamivir phosphate is a water-soluble prodrug. It can be readily dissolved in purified water or aqueous buffers. For liquid formulations, it is typically dissolved in aqueous vehicles with appropriate pH adjustment and stabilizers to ensure chemical stability. Avoid strong acidic or alkaline conditions that may promote degradation. For solid dosage forms, the API is usually blended with suitable excipients and does not require pre-dissolution.

Recommand dosage

Typical therapeutic dosing is determined by a healthcare professional. In marketed products, commonly used strengths include:

Capsules: 30 mg, 45 mg, 75 mg

Oral suspension: equivalent to 6 mg/mL concentration after reconstitution

dult treatment and prophylaxis dosing should follow approved prescribing information and physician guidance. Pediatric dosing is weight-based and requires medical supervision.

Suitable for oral capsules,oral solution or oral suspension and prophylactic and therapeutic antiviral indications for influenza A and B, as directed by clinicians